The effects of interferon alpha2b on chemically-induced peritoneal fibrosis and on peritoneal tissue MMP-2 and TIMP-2 levels in rats.
This study investigated the effect of interferon alpha2b on chlorhexidine gluconate (CH)-induced peritoneal fibrosis (PF) in rats and assessed peritoneal tissue levels of metalloproteinase (MMP)-2 and tissue inhibitors of metalloproteinases (TIMP)-2. Wistar albino rats (n = 8 per group) were treated as follows: control group, 3 ml/day of 0.9% saline intra-peritoneally for 28 days; CH group, 0.1% CH (200 g[3 ml]/day) in 15% ethanol and 0.9% saline intra-peritoneally for 28 days; CH + interferon (IFN) group, CH (as above) plus pegylated IFN-alpha2b 1.5 mug/kg per week subcutaneously on days 0, 7, 14, 21 and 28; IFN group, pegylated IFN-alpha2b (as above). Parietal peritoneum samples were obtained from the left anterior abdominal wall after 35 days. Parietal thickness, degree of vascular proliferation and inflammation, and MMP-2 and TIMP-2 levels were determined. The mean peritoneal thicknesses of the control, CH, CH + IFN and IFN groups were 7.02 +/- 3.89, 156.86 +/- 29.13, 59.88 +/- 22.1, 9.27 +/- 2.03 mum, respectively. Pegylated IFN-alpha2b decreased CH-induced expression of MMP-2 in the parietal peritoneum, but had no effect on TIMP-2 levels. Further studies are needed to determine the optimal dosage and duration for pegylated IFN-alpha2b treatment.
Department of Nephrology, Erzurum Education and Research Hospital, Erzurum, Turkey. edipucar@mail.com
E
E
Ucar
A
A
Borazan
E
E
Semerci
D N
DN
Binici
M
M
Yaldiz
A
A
Aysal
E
E
Altug
C
C
Kuvandik
C
C
Huzmeli
T
T
Yetim
S
S
Canda
D000818:Animals; D000890:Anti-Infective Agents / Q000633:toxicity; D000998:Antiviral Agents / Q000494:pharmacology; D015415:Biomarkers / Q000378:metabolism*; D002710:Chlorhexidine / Q000031:analogs & derivatives / Q000633:toxicity; D004195:Disease Models, Animal; D004337:Drug Carriers; D000077190:Interferon alpha-2; D016898:Interferon-alpha / Q000494:pharmacology*; D008297:Male; D020778:Matrix Metalloproteinase 2 / Q000378:metabolism*; D056627:Peritoneal Fibrosis / Q000139:chemically induced / Q000188:drug therapy* / Q000201:enzymology; D010537:Peritoneum / Q000187:drug effects* / Q000201:enzymology; D011092:Polyethylene Glycols / Q000494:pharmacology*; D051381:Rats; D017208:Rats, Wistar; D011994:Recombinant Proteins; D019716:Tissue Inhibitor of Metalloproteinase-2 / Q000378:metabolism*
D000890:Anti-Infective Agents; D000998:Antiviral Agents; D015415:Biomarkers; D004337:Drug Carriers; D000077190:Interferon alpha-2; D016898:Interferon-alpha; D011994:Recombinant Proteins; D019716:Tissue Inhibitor of Metalloproteinase-2; D011092:Polyethylene Glycols; D020778:Matrix Metalloproteinase 2; C417083:peginterferon alfa-2b; C010882:chlorhexidine gluconate; D002710:Chlorhexidine